Immune mechanisms of protection: can adjuvants rise to the challenge?
about
Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence.The dichotomy (generation of MAbs with functional heterogeneity) in antimalarial immune response in vaccinated/protected mice: a new concept in our understanding of the protective immune mechanisms in malaria.Innate immune responses induced by the saponin adjuvant Matrix-M in specific pathogen free pigs.Clinical features in patients with long-lasting macrophagic myofasciitisMemory CD4 T cells that express CXCR5 provide accelerated help to B cells.Mapping Uncertainties in the Upstream: The Case of PLGA Nanoparticles in Salmon VaccinesVaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunityImmunological adjuvant effect of the peptide fraction from the larvae of Musca domestica.Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.Vaccine adjuvants: putting innate immunity to work.The Adjuvant Activity of Epimedium Polysaccharide-Propolis Flavone Liposome on Enhancing Immune Responses to Inactivated Porcine Circovirus Vaccine in Mice.Adjuvant-enhanced antibody and cellular responses to inclusion bodies expressing FhSAP2 correlates with protection of mice to Fasciola hepaticaInfected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particlesA chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccinationAssessing the safety of adjuvanted vaccines.Current adjuvants and new perspectives in vaccine formulation.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Phytol-derived novel isoprenoid immunostimulants.Synthetic adjuvants for vaccine formulations: phytol derivatives.Challenges in the research and development of new human vaccines.Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.Gold nanoparticles and vaccine development.The life cycle of a T cell after vaccination - where does immune ageing strike?Recombinant vaccines against leptospirosis.Bovine immunoprotection against Rhipicephalus (Boophilus) microplus with recombinant Bm86-Campo Grande antigen.Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection.Plus ça changeThe hope of progressThe Emerging Facets of Non-Cancerous Warburg Effect.
P2860
Q30429719-81FB8594-7EF2-4147-8C87-BC5A459F8E16Q33577949-F64B4B26-DA97-4391-9C91-58EF28F46E9CQ33717300-AC1550CD-44AA-4EA5-97EB-71616B58A7CBQ34582734-A5819AA1-D271-496F-90F3-1B999EE3A267Q34754506-5CB264C2-AEFC-4FD1-8A20-486D1AE27193Q34779079-B2A8DF10-7844-486C-98DE-4CBF213108E3Q34977848-BD6DB2B1-D279-454D-8873-9E3F739ADE3FQ35108944-6AA46425-8A00-4201-943E-B3DBC0D356FEQ35859313-E2D7990E-DEA6-4067-A41E-C18584609F5AQ36079818-D1A884A2-A687-4FBC-85A3-7BE50C6BC8C2Q36168232-01DA7D97-54BE-4517-A91E-ECEC5A01E168Q36285370-442DBE67-9537-4770-91C8-E24ED60B4F73Q36447711-26D43A67-5BA0-4D07-87D6-0D111CB3FBD0Q36458651-3A37CBB1-286E-4613-8B4A-1AF24BA5A776Q36636675-70C58464-B16C-4A7A-A028-AEFA6D9AEC3AQ37421379-D3D21A10-AD84-4B21-885D-498A7614D2D2Q37906961-210E42EC-F204-45CE-9242-FECB8DF44158Q37909424-5BF4AE89-7C4B-4A56-96D5-589C46E41AE8Q37965724-3D097C66-1720-423F-B656-A820F6E615FCQ38008360-F2FF5209-BA08-40D1-9BB9-9F6573FA174CQ38072067-6A3B6D5D-61EA-49F5-AD9C-1C35BBB218E0Q38096300-B20D757F-2A8F-44FB-A4CE-4D8DEAA0E623Q38241377-2E01AD7D-E9F6-4FFC-B8F6-D5BB2B9B1290Q38543673-E35EA765-058E-4331-8FD9-74CCBB37A9AEQ38871207-7E81547A-2C46-4335-8B23-5E821A71A7EBQ40005348-708BFEC8-4740-431C-A34A-EA9C562D6BF6Q40271211-36D60225-1AA8-4F28-9A86-9AF6D37625C5Q40437860-DE1A3AB7-3FB3-4F48-96BC-7211B45A6286Q41722577-EA29C665-93E4-4705-B8F4-AD124C99753DQ42793631-975E4595-A542-4C16-A9C6-6D04EC8426A3Q42793638-74F98995-98E0-4748-BB2C-B36B6F82C25FQ46130601-550387F6-0339-4303-9819-B4851A67BC9F
P2860
Immune mechanisms of protection: can adjuvants rise to the challenge?
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Immune mechanisms of protection: can adjuvants rise to the challenge?
@ast
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en-gb
Immune mechanisms of protection: can adjuvants rise to the challenge?
@nl
type
label
Immune mechanisms of protection: can adjuvants rise to the challenge?
@ast
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en-gb
Immune mechanisms of protection: can adjuvants rise to the challenge?
@nl
prefLabel
Immune mechanisms of protection: can adjuvants rise to the challenge?
@ast
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en-gb
Immune mechanisms of protection: can adjuvants rise to the challenge?
@nl
P2860
P356
P1433
P1476
Immune mechanisms of protection: can adjuvants rise to the challenge?
@en
P2093
Amy S McKee
Megan K L MacLeod
P2860
P2888
P356
10.1186/1741-7007-8-37
P407
P577
2010-04-12T00:00:00Z
P5875
P6179
1016659001